Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Linus Health Advances Early Detection of Brain Health
The year 2026 is already emerging as a pivotal moment for brain health as the healthcare industry faces a growing crisis. Cognitive impairment, Alzheimer’s disease, and other forms of dementia are rising rapidly while early detection and intervention remain inaccessible for millions of people. The number of Americans living with Alzheimer’s and related dementias is expected to double over the next few decades, from roughly 7 million today to nearly 14 million by 2060. With longer life spans and increasing evidence that lifestyle interventions could prevent nearly half of all cases, the importance of early detection has never been greater. At the same time, disease-modifying therapies and blood biomarker testing are showing that timely action can significantly improve outcomes, highlighting the need for scalable, clinically practical solutions across healthcare.
AI Reshapes Cardiac and Cancer Imaging Across Healthcare
The medical imaging industry is undergoing a major transformation as AI-driven solutions redefine how clinicians assess the human heart. The medical image management sector is projected to reach $9.06 billion by 2032, signaling a shift away from traditional, expensive imaging equipment toward software-based diagnostic tools. Point-of-care technologies are also expanding rapidly, with the market expected to reach $70.92 billion. Hospitals are increasingly moving from fixed MRI suites to portable, bedside AI-powered devices that provide hospital-grade precision. This change has created significant opportunities for companies building the digital infrastructure to support these new care models, including VentriPoint Diagnostics, Butterfly Network, Hyperfine, Hologic, and GE HealthCare.
Altru Health System Earns North Dakota Blue Zones Certification
Altru Health System has reached a major milestone in its ongoing commitment to employee wellness by becoming the first organization in North Dakota to earn Certified Blue Zones Worksite status.
AbbVie Reports Phase 3 Epcoritamab Results in DLBCL
AbbVie shared topline findings from the Phase 3 EPCORE DLBCL-1 trial, which evaluated epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, against investigator-chosen chemoimmunotherapy in adult patients with relapsed or refractory diffuse large B-cell lymphoma. The study showed that epcoritamab improved progression-free survival with a hazard ratio of 0.74 and a 95 percent confidence interval ranging from 0.60 to 0.92. Patients treated with epcoritamab also experienced higher complete response rates, longer duration of response, and extended time to next treatment. The trial did not show a statistically significant improvement in overall survival with a hazard ratio of 0.96 and a 95 percent confidence interval of 0.77 to 1.20.
Novartis Ianalumab Gains FDA Breakthrough Status for Sjögren’s Disease
Novartis announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease, the second most prevalent rheumatic autoimmune disease. Ianalumab is a fully human monoclonal antibody with a novel dual mechanism of action that depletes B-cells and inhibits their activation and survival via BAFF-R blockade. Novartis plans to submit ianalumab for regulatory approval globally starting in early 2026. If approved, ianalumab would become the first targeted treatment for patients with Sjögren’s disease.
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Telix Pharmaceuticals Limited announces that the first patient in the United States (U.S.) has been dosed in BiPASS, a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET imaging agents, Illuccix and Gozellix in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.
To share your insights, please write to us at sudipto@intentamplify.com
